Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| NAMSA | OTHER |
Not provided
Not provided
This is a non-interventional study to perform the clinical performance evaluation of the Starfish Test using prospectively collected matched nasopharyngeal and nasal swab samples from the same donor.
The Applied Biosystemsâ„¢ TaqPathâ„¢ COVID-19, Flu A, Flu B, RSV Select Panel (referred to below as "Starfish Test") aims to develop a multiplex real-time PCR IVD test for the qualitative detection and identification of SARS-CoV-2, influenza A virus, influenza B virus, and respiratory syncytial virus (RSV).
The purpose of this performance study is to evaluate the clinical performance of the Starfish Test compared with that of a comparator device using upper respiratory specimens from subjects who have provided consent to participate in the study and meet the inclusion criteria. This Clinical Performance Study Protocol (CPS Protocol) outlines the clinical sample collection and testing protocols which will be used to satisfy the FDA 510(k) study requirements in the US.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| SARS-CoV-2 infection | 50 positive samples 500 negative samples |
| |
| Influenza A infection | 50 positive samples 500 negative samples |
| |
| Influenza B infection | 30 positive samples 500 negative samples |
| |
| RSV infection | 30 positive samples 500 negative samples |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| The Applied Biosystemsâ„¢ TaqPathâ„¢ COVID-19, Flu A, Flu B, RSV Select Panel | Diagnostic Test | A multiplex real-time PCR IVD test for the qualitative detection and identification of SARS-CoV-2, influenza A virus, influenza B virus, and respiratory syncytial virus (RSV). |
| Measure | Description | Time Frame |
|---|---|---|
| Primary Endpoint | The primary endpoint of this clinical performance study is to meet the minimum sample positivity requirements for nasopharyngeal samples as defined by relevant regulatory guidance. | Between February 2023 and April 2024 |
| Measure | Description | Time Frame |
|---|---|---|
| Secondary Endpoint | The secondary endpoint of this study is to complete the clinical performance evaluation of the Starfish Test compared with that of a predicate device using Anterior nasal specimens and meet the minimum PPA and NPA requirements and acceptance criteria for each viral target as summarized in the protocol. | Between February 2023 and April 2024 |
Not provided
Inclusion Criteria:
Participants of all ages must meet the following inclusion criteria to be eligible for participation in the study.
Exclusion Criteria:
Participants meeting the following criterion will be excluded from the study:
Not provided
Not provided
Not provided
Not provided
The study population will be composed of participants suspected of respiratory tract infection from SARS-COV-2, Influenza A/B, or RSV. After a subject is determined eligible for study participation (met inclusion criteria and did not meet exclusion criteria) and has completed the institutional review board (IRB)-approved informed consent form process (or assent, as age appropriate), the subject is enrolled into the study.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Women's Health Care Research | San Diego | California | 92111 | United States | ||
| Medical Center for Clinical Research |
Not provided
Not provided
Not provided
Not provided
The study population will be composed of participants suspected of a respiratory tract infection from SARS-COV-2, Influenza A/B, or RSV. For this study, 1 nasopharyngeal swab and 1 nasal swab will be collected from each participant recruited prospectively from at least three (3) collection sites located in different geographical regions in the US.
| San Diego |
| California |
| 92120 |
| United States |
| Multi-Specialty Research Associates | Lake City | Florida | 32055 | United States |
| D&H National Research Centers | Miami | Florida | 33155 | United States |
| Quantigen | Fishers | Indiana | 46037 | United States |
| KUR Research at Columbia Medical Practice | Columbia | Maryland | 21045 | United States |
| Vida Clinical Studies | Dearborn Heights | Michigan | 48127 | United States |
| MRI Global | Kansas City | Missouri | 64110 | United States |
| Clinical Research Center of Nevada | Las Vegas | Nevada | 89106 | United States |
| KUR Research at AFC Urgent Care | Hillsdale | New Jersey | 07642 | United States |
| KUR Research at AFC Urgent Care | Paramus | New Jersey | 07652 | United States |
| Mako Medical Laboratories | Henderson | North Carolina | 27537 | United States |
| Progressive Medicine of the Triad | Winston-Salem | North Carolina | 27103 | United States |
| ClinSearch | Chattanooga | Tennessee | 37421 | United States |
| Helios Clinical Research | Jackson | Tennessee | 38305 | United States |
| Helios Clinical Research | Keller | Texas | 76248 | United States |
| Granger Medical Clinic | Riverton | Utah | 84096 | United States |
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| D018357 | Respiratory Syncytial Virus Infections |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D014777 | Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D018186 | Pneumovirus Infections |
| D018184 | Paramyxoviridae Infections |
| D018701 | Mononegavirales Infections |
Not provided
Not provided